Table 2.
Outcomes of clinical trials of featured novel agents and treatment combinations in AML from ASH 2022
| Drug | Indication | ORR | CRc | Notable side effects | References |
|---|---|---|---|---|---|
| Magrolimab | ND AML | 81% | 72% | Anemia, infusion reactions | [6] |
| Gilteritinib | ND and R/R AML |
100% (ND) 70% (R/R) |
92% (ND) 20% (R/R) |
Infection | [7] |
| SNDX-5613 (Revumenib) | R/R AML | 53% | 38% | Differentiation syndrome | [3] |
| KO-539 (Ziftomenib) | R/R AML | 40% | 35% | Differentiation syndrome, pneumonitis | [4] |
| Pivekimab sunirine (PVEK) | R/R AML | 45% | 25% | Infusion reactions | [5] |
ND newly diagnosed, R/R relapsed/refractory, ORR overall response rate, encompassing CR/CRh/CRp/CRi/MLFS, CRc composite complete remission, encompassing CR/CRh/CRp